Pfizer Presents Scientific Advancements in Infectious Disease Prevention and Treatments at IDWeek 2022

Pfizer Presents Scientific Advancements in Infectious Disease Prevention and Treatments at IDWeek 2022

Data demonstrate diversity of vaccine andanti-infective portfolio and slice- edge scientific approach to battling viral and bacterial infections
Donations of interest include a late- breaking abstract with the first full data of the efficacity and safety of Pfizer’s bivalent respiratory syncytial contagion( RSVpreF) vaccine seeker in aged grown-ups; and new data regarding PAXLOVID ™( nirmatrelvir( PF- 07321332) tablets and ritonavir tablets), including its effect on COVID-19-related hospitalizations and other medical visits

Pfizer to host “ RSV Data and COVID Vaccine Commercial Update ” call with judges at 430p.m.( EDT) on October 20, 2022
PfizerInc.( NYSE PFE) will partake data across its extensive contagious complaint portfolio, including company- patronized and cooperative exploration studies, gauging both certified and investigational vaccines, and antibiotic and antiviral curatives at IDWeek 2022 held in Washington,D.C. October 19- 23, 2022. Data from 35 objectifications involving Pfizer vaccines andanti-infective curatives will illustrate the diversity of the portfolio and the company’s slice- edge scientific approach. This will include a late- breaking donation of the full data from its Phase 3( NCT05035212) RENOIR( RSV vaccine efficacity study iNOlder grown-ups Immunized against RSV complaint) clinical trial, probing its bivalent RSV A and B, stabilized RSV prefusion F subunit vaccine seeker, RSVpreF, when administered to grown-ups 60 times of age and aged. These data will also be presented on October 20, 2022, to theU.S. Centers for Disease Control and Prevention’s( CDC) Advisory Committee on Immunization Practices( ACIP).

“ The data presented at this time’s IDWeek showcase the breadth of Pfizer’s vaccine and remedial exploration and development portfolio and our uninterrupted commitment to working to overcome contagious conditions that still present a serious health threat, ” said Annaliesa Anderson,Ph.D., elderly Vice President and Chief Scientific Officer, Vaccine Research and Development, Pfizer. “ We look forward to both participating our instigative data, as well as connecting with the scientific community to determine how we can continue to work to bring transformative results to baffle contagious conditions. ”
The exploration to be presented includes new perceptivity on bacterial and viral infections, including Lyme complaint andC. difficile. also, donations will includePfizer’s licensed vaccine, PREVNAR 13 ®( Pneumococcal 13- valent Conjugate Vaccine( Diphtheria CRM197 Protein)), and its investigational vaccine campaigners RSVpreF and Group B Streptococcus, GBS6. Beyond vaccines, Pfizer is also presenting new data regarding PAXLOVID ™( nirmatrelvir( PF- 07321332) tablets and ritonavir tablets), its authorized oral treatment for COVID- 19.
Pfizer Conference Call

PfizerInc. invites Pfizer investors and the general public to view and hear to “ RSV Data and COVID Vaccine Commercial Update, ” a webcast of a live conference call with investment judges at 430p.m. ET on October 20.

To view and hear to the webcast visit Pfizer’s web point atwww.pfizer.com/investors or directly at https//pfizer.rev.vbrick.com/#/events/c5b674a0-5663-4030-a863-16ecfb0a0f9b. Information on penetrating andpre-registering for the webcast will be available atwww.pfizer.com/investors beginning moment. Actors are advised topre-register in advance of the conference call.

You can hear to the conference call by telephoning either800-456-4352 in the United States or Canada or785-424-1086 outside of the United States and Canada. The passcode is “ 48062. ” Please join the call five twinkles previous to the launch time to avoid driver hold times.

The paraphrase and webcast renewal of the call will be made available on Pfizer’s web point atwww.pfizer.com/investors within 24 hours after the end of the live conference call and will be accessible for at least 90 days.

About Pfizer improvements That Change Cases ’ Lives

At Pfizer, we apply wisdom and our global coffers to bring curatives to people that extend and significantly ameliorate their lives. We strive to set the standard for quality, safety and value in the discovery, development and manufacture of health care products, including innovative drugs and vaccines. Every day, Pfizer associates work across developed and arising requests to advance heartiness, forestallment, treatments and cures that challenge the most stressed conditions of our time. harmonious with our responsibility as one of the world’s premier innovative biopharmaceutical companies, we unite with health care providers, governments and original communities to support and expand access to dependable, affordable health care around the world. For further than 170 times, we’ve worked to make a difference for all who calculate on us.

Source link:https://www.pfizer.com/